Nutranomics, Inc. f/k/a Buka Ventures, Inc. (OTCBB:NNRX) Keeps Feeding the Hype

The paid pump on Nutranomics, Inc. f/k/a Buka Ventures, Inc. (OTCBB:NNRX) ended more than a month ago. Since then, the stock has been trading mostly on whatever hype the company can create around itself, and NNRX has been trying hard.

In the last month alone, the company has issued 13 press releases. The latest one came through yesterday morning. NNRX announced it had completed a license agreement to acquire the worldwide exclusive marketing and distributing rights to GenEpic, a natural therapeutic treatment formula.

Following the announcement NNRX managed to close up 3.62% at $0.829 per share on a little over 2.1 million shares. Last Friday, the company announced the official commercial launch of its Glucozyme would begin on Dec. 1, and proceeded to close down 4.19% at $0.80 per share.

All the press releases of NNRX may sound promising to some traders, and it’s exactly these traders who should be careful. The paid pump carried out by the ECA Group, may be over, but it is still a pretty big red flag.

Earlier this year, the same outfit touted Green Innovations Ltd. (OTCBB:GNIN) and iTalk, Inc. (OTCBB:TALK). Both of the companies kept spewing out optimistic press releases about deals and purchase orders after their pumps were over, and both of these stocks have dropped more than 90% from their respective highs.

At this point, NNRX doesn’t have much more than it’s own press releases to keep it’s price at the current levels. When artificially heightened expectations meet with reality, it’s always a painful experience for those who skip the due diligence.